title: Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system.
abstract: One of the earliest descriptions of non-neuronal ACh synthesis was by Morris who reported that ACh was synthesized in the placenta [1]; furthermore, Falugi et al. showed the presence of AChE in human fibrosarcoma cells [2]. Afterward, the expression of ACh, AChE, and cholinergic receptors in non-neuronal cells was reported in several studies [3-16]. Indeed, recent data reported that SCLC expresses a cholinergic autocrine loop that can regulate cell growth. Such work demonstrates that SCLC cells have a cholinergic phenotype and that ACh exerts as an autocrine growth factor in human lung tumours [16]. Moreover, it has been recently reported that nicotine in lung adenocarcinoma A549 cells, potently induces Bad phosphorylation at serine (S)112, S136 and S155 in a mechanism involving activation of MAPKs, ERK1/2, PI3K/AKT and PKA through the linking to alpha7-receptors [9]. Bad phosphorylation results in sequestering Bad from mitochondria and subsequently interacting with 14-3-3 in the cytosol [9]. We have recently reported that human malignant pleural mesothelioma expresses a cholinergic system, involved in cell growth regulation. Hence, mesothelioma cells growth is modulated by the cholinergic system in which agonists (i.e. nicotine) have a proliferative effect and antagonists (i.e. curare or alpha-cobratoxin) have an inhibitory effect. Furthermore apoptosis mechanisms are under the control of the cholinergic system (nicotine antiapoptotic via induction of NF-kappaB complexes and phosphorylation of Bad at S112, curare proapoptotic via G0-G1 arrest p21waf-1-dependent, but p53-independent) [16]. The involvement of the non-neuronal cholinergic system in lung cancer and mesothelioma appears reasonable and opens up new translational research strategies.
authors.affiliation: Translational Research B (Lung Cancer), Department of Integrated Medical Oncology (DOMI) National Cancer Institute (IST), Genoa Italy. patrizia.russo@istge.it
authors.forename: P
authors.initials: P
authors.lastname: Russo
authors.forename: A
authors.initials: A
authors.lastname: Catassi
authors.forename: A
authors.initials: A
authors.lastname: Cesario
authors.forename: D
authors.initials: D
authors.lastname: Servent
mesh_terms: D000109:Acetylcholine / Q000502:physiology; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D018680:Cholinergic Antagonists / Q000494:pharmacology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008654:Mesothelioma / Q000188:drug therapy / Q000473:pathology; D011950:Receptors, Cholinergic / Q000737:chemistry / Q000378:metabolism*; D012910:Snake Venoms / Q000494:pharmacology
chemical_list: D018680:Cholinergic Antagonists; D011950:Receptors, Cholinergic; D012910:Snake Venoms; D000109:Acetylcholine